Board member at Novo Nordisk (NVO) purchases 2,350 ADRs on NYSE
Rhea-AI Filing Summary
Novo Nordisk A/S filed a report showing trading in its American Depositary Receipts (ADRs) by a member of the board of directors. Board member Christina Law purchased Novo Nordisk ADRs on the New York Stock Exchange.
The filing states that she carried out several purchases on 18 August 2025 at prices of DKK 349.06 for 952 ADRs, DKK 349.04 for 598 ADRs and DKK 349.03 for 800 ADRs. In total, this represents an aggregated volume of 2,350 ADRs for a total consideration of DKK 820,252.49, reported in accordance with European market abuse rules.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 19, 2025
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
Page 2 of 3
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Christina Law | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Member of the Board of Directors | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
ADRs | |||
| Identification code | NVO | ||||
| b) | Nature of the transaction | Purchase of ADRs | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| DKK 349.06 | 952 ADRs | ||||
| DKK 349.04 | 598 ADRs | ||||
| DKK 349.03 | 800 ADRs | ||||
| d) |
Aggregated information · Aggregated volume · Price |
2,350 ADRs DKK 820,252.49 | |||
| e) | Date of the transaction | 2025-08-18 | |||
| f) | Place of the transaction | New York Stock Exchange | |||
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Page 3 of 3
Contacts for further information
| Media: | |
|
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com |
Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
|
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
Sina Meyer +45 3079 6656 azey@novonordisk.com |
|
Max Ung +45 3077 6414 mxun@novonordisk.com |
Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com |
|
Alex Bruce +45 3444 2613 axeu@novonordisk.com |
Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 25 / 2025 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: August 19, 2025 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |
FAQ
What insider transaction did Novo Nordisk (NVO) report in this 6-K?
The report shows that board member Christina Law purchased Novo Nordisk American Depositary Receipts (ADRs) on the New York Stock Exchange.
How many Novo Nordisk (NVO) ADRs did the board member buy and at what total value?
Christina Law bought an aggregated 2,350 ADRs for a total consideration of DKK 820,252.49, according to the filing.
On what date did the Novo Nordisk (NVO) board member purchase the ADRs?
The transactions took place on 18 August 2025, as disclosed in the report.
What prices were paid for the Novo Nordisk (NVO) ADR purchases?
The ADRs were purchased in several trades at DKK 349.06 for 952 ADRs, DKK 349.04 for 598 ADRs, and DKK 349.03 for 800 ADRs.
Where are Novo Nordisk (NVO) ADRs traded?
Novo Nordisk ADRs are listed and traded on the New York Stock Exchange under the ticker NVO.
Why does Novo Nordisk (NVO) disclose these insider transactions?
The transactions are disclosed in line with Article 19 of Regulation No. 596/2014 on market abuse, which requires reporting of trades by board members, executives and their associated persons.
